SARS-CoV-2 hijacks lung cells for its own purposes
The first map of molecular responses of human lung cells to SARS-CoV-2 infection has been developed. It shows that the novel coronavirus causes significant protein and phosphorylation damage, effectively hijacking lung cells to enable its entry and propagation, according to a study published in Molecular Cell.  Discuss
Inovio expands COVID-19 vaccine manufacturing with Kaneka
Inovio has brought Belgium-based Kaneka Eurogentec on board a global consortium of companies that will be manufacturing its DNA COVID-19 vaccine INO-4800, which is in phase II/III development.
Lilly to provide U.S. with 650K more COVID-19 antibody doses
The U.S. government has purchased an additional 650,000 doses of Eli Lilly's neutralizing antibody, bamlanivimab, for $812.5 million.
Study unravels why children are more protected from SARS-CoV-2 infection
One of the more puzzling aspects of the COVID-19 pandemic is the resistance of children to the negative effects of infection with the SARS-CoV-2 virus. A new study published December 1 in Archives of Disease in Childhood indicates that this resistance may be due to differences in the immune system, certain blood vessel characteristics, and microbiota composition in children.  Discuss
FasterCures launches pandemic warning initiative
FasterCures, a center of the Milken Institute, has launched an initiative to build a global early warning system to detect and respond to emerging pathogens.
Pfizer, BioNTech COVID-19 vaccine gets emergency approval in the U.K.
The Medicines and Healthcare Products Regulatory Agency in the U.K. has granted a temporary authorization for emergency use for BNT162b2, Pfizer and BioNTech's COVID-19 messenger RNA vaccine.
Pfizer, BioNTech submit CMA to EMA for COVID-19 vaccine
Pfizer and BioNTech submitted an application on November 30 for conditional marketing authorization (CMA) to the European Medicines Agency (EMA) for their messenger RNA vaccine candidate, BNT162b2.
FDA sets advisory meeting date to discuss Moderna COVID-19 vaccine
The U.S. Food and Drug Administration (FDA) has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee for December 17 to discuss the request for emergency use authorization for the COVID-19 vaccine candidate from Moderna.
Should more COVID-19 research be based on mucosal immunity?
As most COVID-19 tests are based on nasal swabs or saliva samples that measure the amount of SARS-CoV-2 virus in the mouth or nose, it is important to understand how immunity to the virus develops in these mucous membranes. In a perspective article published in Frontiers in Immunology on November 30, researchers warned that the large mucosal immune system has been understudied during the pandemic.  Discuss
Novavax provides updates on COVID-19 vaccine
Novavax has reported that it is making "meaningful progress" on its COVID-19 vaccine, NVX‑CoV2373.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter